Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs BIIB 061 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 06 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Mar 2014 New trial record